Two birds, one stone: Drug combo may prove effective against second type of leukemia

Every year, nearly 11,000 Americans die of acute myeloid leukemia (AML), a blood cancer that affects mainly older adults. While most patients initially respond to chemotherapy, more than half of those who respond will eventually relapse as the cancer cells develop resistance to treatment. In a new paper published today in Cell Research, a team of scientists led by Pier Paolo Pandolfi, MD, Ph.D., Director of the Cancer Center and Cancer Research Institute at Beth Israel Deaconess Medical Center, reveal vulnerabilities in a subset of AML that could serve as the foothold researchers need to overcome resistance to therapy.
Read More

>>Hollywood's Exotic Secret For Healthy Weight Loss